ClinicalTrials.gg
CompletedNCT03239340ELIOSUpdated Oct 21, 2024Results posted

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

A Phase 2 interventional study of Osimertinib in EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 26 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
20th of 90
154 · median 51
Started
2018
with 12 others
Phase 2
46 of 90
12 open now
Registered
30th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by enrollment, is one of 13 that started in 2018, is one of 46 in phase 2, and was the 30th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.

Read the detailed description

Study design This is a phase II, open-label, single-arm tissue and plasma acquisition study assessing the efficacy, safety and underlying resistance mechanisms of osimertinib (80 mg orally, once daily) as first-line treatment in patients with locally advanced or metastatic EGFR mutation positive non-small cell lung cancer who are EGFR tyrosine kinase inhibitor treatment-naïve and eligible for first-line treatment. Participants with EGFR mutation-positive non-small cell lung cancer will be required to consent to 2 mandatory tumour biopsies to be considered for enrolment in this study. The first biopsy will be done prior to initiating treatment with osimertinib and the second biopsy will be obtained any time between Investigator assessed, Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)-defined progression and before the start of any new anticancer treatment. A third optional biopsy may be taken during the course of treatment at the Investigator's discretion if the patient consents and if clinically feasible. Tumour tissue and plasma samples will be collected and examined for genetic and non genetic aberrations that may be important in determining response and resistance to the treatment that participants will receive as a part of their cancer care. Patients should continue on osimertinib until progression or until other treatment discontinuation criteria are met. However, if patients continue to show clinical benefit to treatment as judged by the Investigator, patients may continue to receive osimertinib beyond RECIST 1.1-defined progression. Therefore, there is no maximum duration of treatment. Tumour assessments will be performed at baseline and then every 8 weeks from study enrolment until 3.5 years, and then every 10 weeks until RECIST 1.1-defined. Patients will be followed up for a period of 28 days following discontinuation of osimertinib. Target patient population Male and female patients aged 18 years and over with locally advanced or metastatic pathologically confirmed adenocarcinoma of the lung, not amenable to curative surgery or radiotherapy. Patients will have a tumour that harbours one of the EGFR mutations known to be associated with EGFR tyrosine kinase inhibitor sensitivity, either alone or in combination with other EGFR mutations (EGFR mutation status determined by a local laboratory). Patients must be EGFR tyrosine kinase inhibitor treatment-naïve and eligible to receive first line treatment with osimertinib. Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR. Osimertinib (80 mg orally, once daily) will be administered. Doses may be reduced to 40 mg if needed.

03

Conditions studied

  • EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Keywords

  • EGFR, NSCLC, Lung Cancer, Biopsy, Molecular Profiling
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior
  2. Patients aged 18 years or older
  3. Patients with histological confirmation of locally advanced or NSCLC
  4. Patients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)
  5. Patients with an EGFR deletion or mutation known (from tumour or plasma) to be associated with EGFR TKI sensitivity
  6. Existence of measurable or evaluable disease (as per 1.1 criteria).
  7. Possibility of obtaining sufficient tissue sample, via a biopsy or surgical resection of the primary tumour or metastatic tumour tissue
  8. 0-1
  9. ≥12 weeks
  10. Capacity to swallow
  11. Patients able to complete study and within geographical proximity allowing for adequate follow up
  12. Resolution of all acute toxic effects of previous anticancer therapy
  13. Female patients must be using highly effective measures, and must have a negative pregnancy test prior to start of dosing if of
  14. Male patients must be willing to use barrier contraception

Exclusion criteria

Exclusion Criteria:

  1. Locally advanced lung cancer candidate for curative treatment through radical surgery and/or radio(chemo)therapy
  2. Patients diagnosed with another lung cancer subtype
  3. Patients with an EGFR exon 20 insertion
  4. Patients with just one measurable or evaluable tumour lesion that has been resected or irradiated prior to their enrolment in the study
  5. Second active neoplasia
  6. Treatment with an drug within five half-lives of the compound
  7. Participation in another clinical study with an investigational product (IP) during the last 3 weeks before the first day of study treatment
  8. Patients who have received prior immunotherapies
  9. Patients who have received prior EGFR treatments for lung cancer
  10. Patients who have received prior treatment with an EGFR TKI including in the setting
  11. Patients who have received previous treatment for or stage IV disease
  12. Prior treatment with cytotoxic chemotherapy for advanced NSCLC
  13. Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than 6 months prior and/or have received a bone marrow transplant less than 2 years before the first day of study treatment
  14. Any unresolved toxicities from prior therapy greater than grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy
  15. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or active infection (eg, patients receiving treatment for infection) including and (HIV), or active uncontrolled virus (HBV) infection.
  16. Patients who have had a surgical procedure unrelated to the study within 14 days or major surgery within 1 month prior to the administration of the study drug
  17. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis
  18. Any of the following cardiac criteria: Mean resting corrected for heart rate (QTc) more than 470 msec, obtained from 3 ECGs, using the screening clinic machine derived QTc value. Any abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, hypomagnesaemia, hypocalcaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
  19. Spinal cord compression, symptomatic and unstable except for those patients who have completed definitive therapy, and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. 20. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib

21.Inadequate bone marrow reserve or organ function 22.Female patients who are breastfeeding 23.Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome (CYP) 3A4.

24.Patient unwilling to undergo a at the time of disease progression 25.History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib 26.Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements 27.Involvement in the planning and/or conduct of the study 28.Previous enrolment in the present study

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Osimertinib

    An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer

    Drug: Osimertinib

Interventions

  • Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.

    Also known as: TAGRISSO, AZD9291

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression

    The frequency of genetic and proteomic markers at disease progression regardless of their prevalence was evaluated.

    Time frame: Genetic and proteomic markers were assessed at baseline and progression (up to 5 years after baseline)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression.

    Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years

  2. Objective Response Rate (ORR)

    ORR is defined as the number (%) of patients with at least one visit response of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later.

    Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years

  3. Duration of Response (DoR)

    Duration of response is defined as the time from the date of first documented response, (that is subsequently confirmed) until date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit that was CR or PR that was subsequently confirmed.

    Time frame: From date of first documentation of complete/partial response until the date of progression, or last evaluable RECIST assessment for participants that did not progress within 2 missed visits of last assessment, up to 5 years

  4. Disease Control Rate (DCR)

    DCR is defined as percentage of patients with confirmed complete response, confirmed partial response or with stable disease.

    Time frame: 8 weeks

  5. Time to Treatment Discontinuation or Death (TTD)

    TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death.

    Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years

  6. Time to First Subsequent Therapy or Death (TFST)

    TFST is defined as the time from the date of first dose of osimertinib to the earlier of the date of anticancer therapy start date following study treatment discontinuation, or death.

    Time frame: From date of first dose to start of subsequent anticancer therapy or death (by any cause in the absence of recurrence), up to 5 years

  7. PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline

    PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: EGFR tumor mutation at baseline-Exon19del or L858R

    Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years

  8. PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline

    PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: Exon19del or L858R detectable in plasma derived circulating tumour deoxyribonucleic acid (ctDNA) at baseline.

    Time frame: From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years

  9. ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

    ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R

    Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years

  10. ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

    ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.

    Time frame: From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years

  11. TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

    TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R

    Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years

  12. TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

    TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.

    Time frame: From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years

  13. Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

    Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R. A negative change denotes a reduction in target lesion size.

    Time frame: From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years

  14. Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

    Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline. A negative change denotes a reduction in target lesion size.

    Time frame: From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years

07

Results

Posted Sep 19, 2024

Participant flow

Participants were enrolled in this study from 30 May 2018 (First subject in) and analyses presented in this results form are based on a final data cut-off of 18 July 2023 and final database lock of 15 December 2023.

Participant flow — Overall Study
MilestoneOsimertinib 80mg
Started154
Completed33
Not completed121
Withdrew: Other26
Withdrew: Patients who are ongoing in the study at dco10
Withdrew: Death40
Withdrew: Lost to follow-up2
Withdrew: Physician decision16
Withdrew: Withdrawal by subject27

Outcome measures

PrimaryProportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression

The frequency of genetic and proteomic markers at disease progression regardless of their prevalence was evaluated.

Time frame:
Genetic and proteomic markers were assessed at baseline and progression (up to 5 years after baseline)
Reported as:
Number · Percentage of participants
Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression
Percentage of participantsOsimertinib 80 mg
AKT2; Copy Number Alteration: Type; amplification2.0 (0.05 to 10.45)
ALK; Rearrangement3.9 (0.48 to 13.46)
APC; Copy Number Alteration; Type: loss2.0 (0.05 to 10.45)
ARAF; Copy Number Alteration; Type: amplification3.9 (0.48 to 13.46)
ASXL1; Short Variant; Type: Q588*2.0 (0.05 to 10.45)
ATRX; Short Variant; Type: P599fs*222.0 (0.05 to 10.45)
AXL; Copy Number Alteration; Type: amplification2.0 (0.05 to 10.45)
BCL2L2; Copy Number Alteration; Type: amplification3.9 (0.48 to 13.46)
BRAF; Rearrangement2.0 (0.05 to 10.45)
BRAF; Short variant; Type: G469A2.0 (0.05 to 10.45)
BRAF; Short variant Type: V600E3.9 (0.48 to 13.46)
CBL; Short Variant; Type: R149Q2.0 (0.05 to 10.45)
CCND1 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
CCNE1 Copy Number Alteration Type: amplification5.9 (1.23 to 16.24)
CDK4 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
CDK6 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
CDKN1B Short Variant Type: S2*2.0 (0.05 to 10.45)
CDKN2A Copy Number Alteration Type: loss15.7 (7.02 to 28.59)
CDKN2A; Short Variant Type: P38L2.0 (0.05 to 10.45)
CDKN2B Copy Number Alteration Type: loss15.7 (7.02 to 28.59)
CRKL Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
CUL4A Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
DIS3 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
EGFR Copy Number Alteration Type: amplification11.8 (4.44 to 23.87)
EGFR Rearrangement2.0 (0.05 to 10.45)
EGFR Short Variant Type: C797S7 (5.70 to 26.26)
EGFR Short Variant Type: L858R2.0 (0.05 to 10.45)
EMSY Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
ERBB2 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
FANCG Rearrangement2.0 (0.05 to 10.45)
FGF10 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
FGF14; Copy Number Alteration; Type: amplification2.0 (0.05 to 10.45)
FGF19 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
FGFR1 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
FGFR3 Rearrangement2.0 (0.05 to 10.45)
FGFR4 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
HGF Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
HRAS Short Variant Type: Q61R2.0 (0.05 to 10.45)
IDH1 Short Variant Type: R132L2.0 (0.05 to 10.45)
IGF1R Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
IRS2 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
KRAS Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
LYN Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
MAP2K1 Short Variant Type: E102_I103del2.0 (0.05 to 10.45)
MCL1 Copy Number Alteration Type: amplification5.9 (1.23 to 16.24)
MDM2 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
MET Copy Number Alteration Type: amplification17.6 (8.40 to 30.87)
MTAP Copy Number Alteration Type: loss13.7 (5.70 to 26.26)
MYC Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
MYCN Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
NF1 Short Variant Type: M1I2.0 (0.05 to 10.45)
NFE2L2 Short Variant Type: D29N2.0 (0.05 to 10.45)
NFKBIA Copy Number Alteration Type: amplification9.8 (3.26 to 21.41)
NKX2-1 Copy Number Alteration Type: amplification9.8 (3.26 to 21.41)
NOTCH3 Rearrangement2.0 (0.05 to 10.45)
NTRK1 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
PARP1 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
PDGFRB Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
PIK3CA Short Variant Type: E542K2.0 (0.05 to 10.45)
PIM1 Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
RAD21 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
RB1 Copy Number Alteration Type: loss3.9 (0.48 to 13.46)
RB1 Short Variant Type: Q846*2.0 (0.05 to 10.45)
RICTOR Copy Number Alteration Type: amplification7.8 (2.18 to 18.88)
SMAD4 Rearrangement2.0 (0.05 to 10.45)
SMAD4 Short Variant Type: W524L2.0 (0.05 to 10.45)
SPEN Short Variant Type: D2047fs*172.0 (0.05 to 10.45)
STK11 Copy Number Alteration Type: loss2.0 (0.05 to 10.45)
STK11 Short Variant Type: K269fs*182.0 (0.05 to 10.45)
TERC Copy Number Alteration Type: amplification2.0 (0.05 to 10.45)
TERT Short Variant Type: promoter -146C>T2.0 (0.05 to 10.45)
TET2 Short Variant Type: Q916*2.0 (0.05 to 10.45)
TET2 Short Variant Type: V1862fs*132.0 (0.05 to 10.45)
TP53 Short Variant Type: R213*2.0 (0.05 to 10.45)
WHSC1L1 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
ZNF703 Copy Number Alteration Type: amplification3.9 (0.48 to 13.46)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression.

Time frame:
From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsOsimertinib 80 mg
Progression Free Survival (PFS)16.4 (12.7 to 20.3)
SecondaryObjective Response Rate (ORR)

ORR is defined as the number (%) of patients with at least one visit response of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later.

Time frame:
From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsOsimertinib 80 mg
Objective Response Rate (ORR)73.4 (65.66 to 80.17)
SecondaryDuration of Response (DoR)

Duration of response is defined as the time from the date of first documented response, (that is subsequently confirmed) until date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit that was CR or PR that was subsequently confirmed.

Time frame:
From date of first documentation of complete/partial response until the date of progression, or last evaluable RECIST assessment for participants that did not progress within 2 missed visits of last assessment, up to 5 years
Reported as:
Median · Months
Duration of Response (DoR)
MonthsOsimertinib 80 mg
Duration of Response (DoR)18.8 (14.2 to 22.3)
SecondaryDisease Control Rate (DCR)

DCR is defined as percentage of patients with confirmed complete response, confirmed partial response or with stable disease.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsOsimertinib 80 mg
Disease Control Rate (DCR)94.8 (90.02 to 97.73)
SecondaryTime to Treatment Discontinuation or Death (TTD)

TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death.

Time frame:
From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
Time to Treatment Discontinuation or Death (TTD)
MonthsOsimertinib 80 mg
Time to Treatment Discontinuation or Death (TTD)20.0 (16.3 to 23.8)
SecondaryTime to First Subsequent Therapy or Death (TFST)

TFST is defined as the time from the date of first dose of osimertinib to the earlier of the date of anticancer therapy start date following study treatment discontinuation, or death.

Time frame:
From date of first dose to start of subsequent anticancer therapy or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
Time to First Subsequent Therapy or Death (TFST)
MonthsOsimertinib 80 mg
Time to First Subsequent Therapy or Death (TFST)32.1 (24.0 to 47.7)
SecondaryPFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline

PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: EGFR tumor mutation at baseline-Exon19del or L858R

Time frame:
From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline
MonthsExon19delL858R
PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline22.0 (16.0 to 27.6)12.9 (10.8 to 18.2)
SecondaryPFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline

PFS is defined as the time from first dose of osimertinib until the date of Investigator assessed Response Evaluation Criteria in Solid Tumours (RECIST) 1.1-defined progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression. PFS was analysed in patient subgroups defined by molecular profile, including but not limited to: Exon19del or L858R detectable in plasma derived circulating tumour deoxyribonucleic acid (ctDNA) at baseline.

Time frame:
From date of first dose until date of progression or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline
MonthsExon19delL858R
PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline19.6 (12.7 to 24.0)13.7 (9.0 to 18.2)
SecondaryORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R

Time frame:
From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
Reported as:
Number · Percentage of participants
ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
Percentage of participantsExon19delL858R
ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline82.4 (72.57 to 89.77)69.0 (55.46 to 80.46)
SecondaryORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

ORR is defined as the number (%) of patients with at least one visit response of complete response or partial response that is confirmed at least 4 weeks later. ORR was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.

Time frame:
From date of first dose until progression, or last evaluable assessment in the absence of progression, up to 5 years
Reported as:
Number · Percentage of participants
ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
Percentage of participantsExon19delL858R
ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline85.5 (74.22 to 93.14)71.7 (56.54 to 84.01)
SecondaryTTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R

Time frame:
From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
MonthsExon19del 80 mgL858R
TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline25.5 (19.6 to 32.1)16.5 (12.1 to 21.7)
SecondaryTTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

TTD is defined as the time from the date of first dose of osimertinib to the earliest of treatment discontinuation or death. TTD was analysed in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline.

Time frame:
From date of first dose to treatment discontinuation or death (by any cause in the absence of recurrence), up to 5 years
Reported as:
Median · Months
TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
MonthsExon19del 80 mgL858R
TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline24.5 (17.8 to 29.6)16.5 (12.1 to 21.4)
SecondaryTumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline

Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: EGFR tumor mutation at baseline-Exon19del or L858R. A negative change denotes a reduction in target lesion size.

Time frame:
From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years
Reported as:
Median · Percentage change
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline
Percentage changeExon19delL858R
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline-59.68 (-100.0 to 6.5)-54.29 (-100.0 to 7.6)
SecondaryTumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline

Tumour shrinkage is defined as the best change from baseline in the sum of diameters of target lesions, in patient subgroups defined by molecular profile: Exon19del or L858R detectable in plasma derived ctDNA at baseline. A negative change denotes a reduction in target lesion size.

Time frame:
From date of first dose until last recorded post baseline RECIST target lesion assessment scan, up to 5 years
Reported as:
Median · Percentage change
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline
Percentage changeExon19delL858R
Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline-60.80 (-100.0 to 6.5)-58.33 (-100.0 to 7.6)

Adverse events

Collected over From Day 1 to Follow-up (28 days post last dose) up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib 80 mg40/154 (26%)53/154 (34.4%)148/154 (96.1%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventOsimertinib 80 mg
PneumoniaInfections and infestations12/154
SepsisInfections and infestations4/154
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/154
Urinary tract infectionInfections and infestations3/154
Atrial fibrillationCardiac disorders3/154
GastritisGastrointestinal disorders3/154
GastroenteritisInfections and infestations2/154
HyponatraemiaMetabolism and nutrition disorders2/154
Acute coronary syndromeCardiac disorders2/154
Cardiac failureCardiac disorders2/154
Most frequent other events
Showing 10 of 34
Most frequent other events
EventOsimertinib 80 mg
DiarrhoeaGastrointestinal disorders63/154
ParonychiaInfections and infestations36/154
CoughRespiratory, thoracic and mediastinal disorders32/154
Dry skinSkin and subcutaneous tissue disorders30/154
Decreased appetiteMetabolism and nutrition disorders27/154
AnaemiaBlood and lymphatic system disorders26/154
RashSkin and subcutaneous tissue disorders26/154
Upper respiratory tract infectionInfections and infestations24/154
PruritusSkin and subcutaneous tissue disorders23/154
StomatitisGastrointestinal disorders22/154

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Osimertinib 80mg
Mean62.7 ± 10.36
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib 80mg
Female92
Male62
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Osimertinib 80mg
White30
Black or African American5
Asian118
Other1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Osimertinib 80mg
Hispanic6
Not Hispanic or Latino148
08

Study locations

26 sites
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Atlanta, Georgia 30307, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Brescia, 25100, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Parma, 43126, Italy
  • Research Site
    Roma, 00152, Italy
  • Research Site
    Terni, 05100, Italy
  • Research Site
    Busan, 47392, Korea, Republic of
  • Research Site
    Cheongiu, 28644, Korea, Republic of
  • Research Site
    Seongnam, 13620, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Johor Bahru, 81100, Malaysia
  • Research Site
    Kuantan, 25100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Lembah Pantai, 59100, Malaysia
  • Research Site
    Pulau Pinang, 10450, Malaysia
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Las Palmas de Gran Canaria, 35016, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Sevilla, 41009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Sep 2023, 63 months.

Results were first posted in Sep 2024, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 63 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2017
First posted
Aug 4, 2017
StartActual
May 30, 2018
Primary completionActual
Sep 19, 2023
CompletionActual
Sep 19, 2023
Results first posted
Sep 19, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03239340
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 4, 2017
Start date
May 30, 2018
Primary completion
Sep 19, 2023
Completion
Sep 19, 2023
Results posted
Sep 19, 2024
Last update
Oct 21, 2024

Study contacts

Zosia Piotrowska, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion